Outset Medical (NASDAQ:OM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Outset Medical (NASDAQ:OM) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

OM has been the topic of several other research reports. BTIG Research cut their target price on Outset Medical from $39.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, November 11th. Royal Bank Of Canada lowered their price objective on shares of Outset Medical from $22.00 to $17.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 8th. Finally, Stifel Nicolaus set a $14.00 target price on shares of Outset Medical and gave the company a “buy” rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Outset Medical Stock Performance

OM opened at $3.97 on Friday. The company has a market capitalization of $72.07 million, a price-to-earnings ratio of -0.30 and a beta of 2.03. The business’s 50-day moving average price is $9.13 and its two-hundred day moving average price is $13.92. Outset Medical has a 1 year low of $3.94 and a 1 year high of $25.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77.

Hedge Funds Weigh In On Outset Medical

Institutional investors have recently added to or reduced their stakes in the company. Durable Capital Partners LP bought a new position in shares of Outset Medical in the 1st quarter valued at about $19,247,000. Alyeska Investment Group L.P. bought a new position in Outset Medical during the first quarter worth about $18,836,000. T. Rowe Price Investment Management Inc. acquired a new position in Outset Medical during the first quarter worth approximately $17,730,000. Woodline Partners LP acquired a new position in Outset Medical during the first quarter worth approximately $14,663,000. Finally, Pura Vida Investments LLC raised its stake in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after buying an additional 424,120 shares during the period.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.